What question did this study set out to answer?

To develop a standardized protocol for mitigating ICANS in high-risk elderly patients treated with CAR-T therapy.

December 8, 2025BloodOpen Access

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

View Full Paper

Ask AI

Bookmark

Authors

EJErel JoffeMemorial Sloan Kettering Cancer Center TSTamir ShragaiTel Aviv University SPSinem PerkArgonne National Laboratory

Discussion

Member takes

Implication

Pilot study shows tailored ICANS mitigation using corticosteroids and levetiracetam reduces neurotoxicity in high-risk elderly patients receiving CAR-T cells, highlighting infection risk.

Key Points

To develop a standardized protocol for mitigating ICANS in high-risk elderly patients treated with CAR-T therapy.
Single-center prospective pilot study conducting at Tel Aviv Sourasky Medical Center.
Included patients aged ≥75 years or ≥65 years with additional risk factors.
Utilized seizure prophylaxis, corticosteroids, and anakinra based on ICANS grades.
67% of patients experienced ICANS, with 31% developing grade ≥3 events.
Median ICANS duration was 4 days, shorter than historical comparisons.
42% of patients experienced infections, contributing to a 3-month non-relapse mortality of 26.1%.

Cite This Study

Joffe et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d582 https://doi.org/10.1182/blood-2025-1943

View Full Paper

Ask AI

Bookmark

Implication

Pilot study shows tailored ICANS mitigation using corticosteroids and levetiracetam reduces neurotoxicity in high-risk elderly patients receiving CAR-T cells, highlighting infection risk.

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

Discussion

Member takes

Implication

Key Points

Cite This Study

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider